The Right Drug for The Right Patient

ABOUT YZY MED

Founded in 2011, with personalized diagnosis and treatment of cardiovascular, tumor as the strategic direction, Wuhan YZY Medical Science and Technology Co., Ltd. (YZY MED) is a high-tech enterprise specializing in the R&D, production and sales of individualized medical diagnostic products. The company has established various technical platforms, including ARMS fluorescence qPCR, multiple fluorescence qPCR, fluorescence in situ hybridization (FISH) and circulating tumor cell detection, etc. Meanwhile, the self-developed products include molecular diagnostic products to guide personalized medicine for cardiovascular and cerebrovascular diseases, companion diagnostic products to guide tumor diagnosis and treatment, FISH products and circulating tumor cell (CTC) autoanalyzer system, all these provide clinical diagnosis basis for precision medicine.

With a R&D center of 2,000㎡and GMP-accredited industrialized workshop of 3,200㎡,YZY MED has successfully developed over 160 genetic diagnostic products and multiple in vitro diagnostic (IVD) devices, among which nearly 20 molecular diagnostic kits have been approved by the NMPA Class III medical device registration and approval, more than 110 products have passed the CE certification.

Hospitals

0 +

Quality Assurance

ISO 0

CE Certificates

0 +

Authorized Patents

0 +

COMPANY PROFILE

YZY MED is a leading precision diagnostic company specializing in providing comprehensive one-stop solutions for cancer management.

Leading Market Share in Molecular Diagnosis for Pharmacogenomics (PGx)

After more than 10 years of technology accumulation and clinical application, YZY MED has become the leading enterprise in pharmacogenomics in China, with a high market share. The company will continue to launch new products, aiming to consolidate the leading position in this segment.

Complete Target Certificates for Companion Diagonostics Reagents (CDx)

YZY MED is one of the enterprises with the most completent product line in companion diagonostics. Through continuous technology accumulation and market validation, the company has maintained rapid sales growth with more than 100,000 tests.

The First Autoanalyzer System on Circulating Tumor Cell (CTC) Certified in China

YZY MED is the first enterprise in China to carry out liquid biopsy technology. CTCBIOPSY® system is the first NMPA approved system in China with more than 50,000 clinical validation.The company continues to maintain its leading position in the field of liquid biopsy through continuous technology accumulation and clinical data.

Business Achievement

YZY MED attaches great importance on innovation and R&D, R&D personnels account for more than 30%. It has applied for more than 110 patents, obtained over 70 patents authorized. The products have been sold to more than 20 countries and regions around the world, and have accessed into over 600 large and medium-sized hospitals with good market feedback, establishing an industry position in the field of personalized medicine.

Adhering to the mission of “The right drug for the right patient”, YZY MED strives to become a leading enterprise in the field of personalized diagnosis and treatment.

Global Expansion

Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.

Contact Us